Verhey Frans R J, Visser Pieter J
MUMC, Alzheimer Centrum Limburg, Maastricht, the Netherlands.
Ned Tijdschr Geneeskd. 2013;157(11):A5596.
An increasing number of people with mild cognitive impairment (MCI) visits a memory clinic to find out whether their symptoms indicate Alzheimer's disease (AD). Markers in cerebrospinal fluid are increasingly used for the diagnosis of Alzheimer's disease. In the short term, CSF biomarkers are more accurate in ruling out progression to AD-type dementia than demonstrating progression. The predictive value of the CSF biomarkers increases with longer-duration follow-up and declines with age. The added value of CSF biomarkers is not yet clear in MCI patients in whom extensive clinical, neuropsychological examination or imaging have already been performed.
越来越多的轻度认知障碍（MCI）患者前往记忆诊所，以查明他们的症状是否预示着阿尔茨海默病（AD）。脑脊液中的标志物越来越多地用于阿尔茨海默病的诊断。短期内，脑脊液生物标志物在排除向AD型痴呆进展方面比证明进展更准确。脑脊液生物标志物的预测价值随着随访时间的延长而增加，随年龄增长而下降。在已经进行了广泛临床、神经心理学检查或影像学检查的MCI患者中，脑脊液生物标志物的附加价值尚不清楚。
